How New Diabetes, Cardiac, Nutrition and Cancer Tools At Abbott Laboratories (ABT) Have Changed Its Investment Story

• In recent weeks, Abbott Laboratories received FDA authorization for its Libre Duo 10 Day dual glucose‑ketone sensor, advanced its TactiFlex Duo AFib ablation catheter toward U.S. approval, launched Similac 360 Total Care Made With Whole Milk in ready‑to‑feed form, and partnered with the Colorectal Cancer Alliance on an at‑home screening education hub.
• Taken together, these moves highlight how Abbott is extending its reach across diabetes care, cardiac rhythm management, infant nutrition, and cancer screening with new, clinically oriented offerings.
• Next, we’ll examine how Libre Duo 10 Day’s dual glucose‑ketone sensing and Abbott’s broader product launches may influence its investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Abbott Laboratories Investment Narrative Recap

To own Abbott, you need to believe its diversified portfolio in diabetes care, cardiac devices, nutrition, and diagnostics can offset headwinds in diagnostics and foreign exchange, while funding continued product innovation. The latest Libre Duo, TactiFlex Duo, Similac whole-milk launch, and colorectal screening education hub reinforce that innovation story, but they do not appear to materially change the near term focus on diabetes pricing pressure and ongoing litigation as key swing factors.

Among the recent developments, the FDA authorization of Libre Duo 10 Day looks most relevant, because it sits squarely in Abbott’s core diabetes franchise where competitive bidding and pricing pressure remain a central risk. Libre Duo’s dual glucose ketone sensing and integration into the broader Libre ecosystem could be important to how investors think about the resilience and differentiation of this business line relative to peers.

Yet alongside these product wins, investors should be aware of the ongoing threats to Abbott’s diabetes pricing power and margins...

Read the full narrative on Abbott Laboratories (it's free!)

Abbott Laboratories' narrative projects $60.4 billion revenue and $9.5 billion earnings by 2029. This requires 9.0% yearly revenue growth and a $4.1 billion earnings increase from $5.4 billion today.

Uncover how Abbott Laboratories' forecasts yield a $119.12 fair value, a 10% upside to its current price.

Exploring Other Perspectives

Five Simply Wall St Community members currently value Abbott between US$119.13 and US$150.72 per share, reflecting a wide spread of expectations. Against that backdrop, concerns about US competitive bidding and potential commoditization in continuous glucose monitoring could meaningfully shape how these different views play out over time, so it makes sense to weigh several perspectives before forming your own.

Explore 5 other fair value estimates on Abbott Laboratories - why the stock might be worth just $119.12!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Abbott Laboratories research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Abbott Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Abbott Laboratories' overall financial health at a glance.

Searching For A Fresh Perspective?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com